

CREATInG Initiative
Executive Development Program
Impactful Interventions for IVD Access
in Global Markets

PROGRAM BOOKLET

27-29 September 2025
Duke Kunshan University
China

CONTENTS

Welcome Letter	3
Program Directors	4
Program Co-orchestrators.....	7
Agenda	9
Speakers	17
Learning Journal	32
List of Attendance.....	59
Campus Map and Meal Plans	60
Immersion Learning.....	62
Emergency Contact.....	63
Arrive @ Duke Kunshan University	64
Local Attraction – The Water Town.....	65

Welcome Letter

On behalf of the Duke-NUS Centre of Regulatory Excellence (CoRE), the Duke Kunshan University (DKU) and the Gates Foundation, we welcome you to the CREATInG Initiative Executive Development Program: “Impactful Interventions for IVD Access in Global Markets”.

The CREATInG Initiative, a project commissioned by the Gates Foundation and co-led by Duke-NUS CoRE and DKU, aims to accelerate access to in-vitro diagnostics for critical global health needs. With a focus on infectious diseases as well as maternal and fetal health, this initiative aims to bridge the regulatory and market access gaps, ensuring timely, reliable diagnostics reach the communities that need them most.

Recognising that such challenges require collective action, we welcome a broad range of stakeholders to address regulatory and access gaps in our increasingly interconnected world. This highly selective executive development program will use an interactive approach for regional and global speakers and participants from international organisations, global regulatory experts, in-vitro diagnostic manufacturers and other stakeholders to collectively discuss issues and consider innovative approaches to facilitate access of timely and reliable diagnostics to support optimal care to populations.

We look forward to your active participation during the discussions and trust that you will find this executive development program both relevant and enriching and help contribute to strengthening healthcare systems globally.

Prof John Lim

Executive Director

Centre of Regulatory Excellence

Duke-NUS Medical School

Senior Advisor

Ministry of Health, Singapore

Prof Fujie Xu

Co-Director

Global Health Program

Duke Kunshan University

China

Program Directors

Professor Lim CW John



Professor John CW Lim is founding Executive Director of the Centre of Regulatory Excellence (CoRE) at the Duke-National University of Singapore Medical School (Duke-NUS), Senior Advisor at Singapore's Ministry of Health (MOH), and Policy Core Lead at the SingHealth Duke-NUS Global Health Institute. He was inaugural Chairman of the Consortium for Clinical Research & Innovation Singapore and former Chief Executive Officer of Singapore's Health Sciences Authority.

Professor Lim is an experienced healthcare professional, government administrator, national regulator and regulatory science thought leader. He graduated in medicine from NUS and has postgraduate degrees in public health from NUS and health policy and management from Harvard University. He holds joint academic appointments at Duke-NUS and the NUS Saw Swee Hock School of Public Health.

He is a member of the US Pharmacopeia Board of Trustees, Singapore Medical Council, ACCESS Health International Global Board, Centre for Innovation in Regulatory Science Scientific Advisory Council, and the Global Harmonization Center Advisory Board. He was formerly on the Singapore Food Agency and St Andrew's Mission Hospital Boards, among others.

Professor Lim has been awarded the DIA Global Connector Inspire Award and Regulatory Affairs Professional Society's Founder's Award for leadership in promoting global collaboration, and shaping regulatory practice and policy throughout his career. In 2025, he received the US Pharmacopeia President's Award for enhancing regulatory science, promoting medicines quality, and supporting global health by fostering regulatory and scientific collaboration.

Professor Silke Vogel




At Duke-NUS Medical School, expanding on her research and education expertise, she now holds three major leadership portfolios. In her role as Senior Associate Dean of Graduate Studies she leads the administrative, academic, and educational affairs of three PhD programs with the goal to enable each graduate student to achieve academic excellence in their PhD degree and realise their career goals. Since taking on the role of Deputy Director at the founding of the Centre of Regulatory Excellence (CoRE) in 2014, Prof Vogel drives the implementation of the strategic goals of the Centre and continuously advances CoRE as a dedicated training platform for regulatory sciences. Under her leadership, the Graduate Certificate Program in Health Products Regulation established itself as CoRE's flagship program and is the first dedicated academic regulatory training program in Asia.

Stemming from her work with the Graduate Programmes and CoRE, Prof Vogel is passionate about providing opportunities for working professionals who strive to upskill and advance their careers. Building on this, she is now heading the newly established Centre for Lifelong Learning (CLL) at Duke-NUS with the overarching goal to establish a comprehensive learning hub for healthcare professionals. Under the CLL umbrella, several NUS accredited programs as well as short courses are being offered with a planned expansion over the next year. Prof Vogel's leadership of CLL includes working together with faculty and clinician-educators on the identification of gaps in capacities or capabilities that could be addressed through the CLL, and advising on the pedagogy, course structures and implementation through NUS on the accreditation processes for Executive, Graduate Certificates as well Master's programs.

A scientist by training, prior to joining Duke-NUS Medical School, Professor Silke Vogel worked at Columbia University in the Department of Preventive Medicine as an Assistant Professor (tenure track), directing a research laboratory with a focus on understanding factors involved in the development of obesity and insulin resistance. During this time, she participated in teaching Master of Science students and health care professionals in the Institute of Human Nutrition.

Professor Shenglan Tang



Dr. Shenglan Tang is Mary D.B.T. and James Semans Professor at Department of Population Health Science in the Duke University School of Medicine and Research Professor of Global Health in the Duke Global Health Institute (DGHI). He is also a professor of global health at Duke-Kunshan University, and SingHealth-Duke-NUS Global Health Institute in Singapore. Recently Dr. Tang has been re-appointed to be director for global health at Duke Kunshan University, China.

Dr. Tang has more than 30 years of experience undertaking research on health systems reform, disease control and maternal and child health in China and other countries, and has provided consultancy services on health systems strengthening to many international organizations and governments of developing countries. In 2012, Dr. Tang came to Duke from the UNICEF/UNDP/World Bank/WHO Special Program for Research and Training in Tropical Diseases (TDR), based in Geneva, where he was Unit Leader for TB/HIV and Health Systems. Before his assignment at WHO, Tang was a faculty member at Liverpool School of Tropical Medicine in UK and at the School of Public Health of Fudan University (formerly Shanghai Medical University).

Professor Fujie Xu



Her research interests focus on outbreak detection and health emergency response, and she was a “disease detective” in the global response to epidemics and pandemics, including the SARS outbreak and the H1N1 influenza pandemic. During “peace” time, her research focuses on the introduction of new vaccines, diagnostics and treatments against infectious diseases in the United States, China and other Asian countries. She has published widely on various aspects of infectious diseases, particularly HIV/STD, viral hepatitis infections, and emerging and re-emerging infections. She has extensive experience in health product innovations. Prior to her appointment at DKU in January 2025, she was the Deputy Director for Health Innovation and Partnership at the Gates Foundation’s China Country Office.

Her teaching interests at Duke Kunshan include an introduction to global health institutions, global health challenges, and large-scale global health practice and programs.

Xu received an MD in preventive medicine from Peking University and a PhD in epidemiology from Emory University. She did her postdoctoral training as an EIS officer at US CDC in Atlanta.

Program Co-orchestrators

Mr. Fatt-Heng Wong



Mr. Wong Fatt Heng is a distinguished leader in the healthcare and diagnostics industry with over 40 years of experience. As the Founder and General Manager of IVD Consulting Co. Ltd. since 2023, he leverages his extensive expertise to provide strategic guidance to industry stakeholders. Previously, Mr. Wong held key leadership roles including CEO of DIAN Diagnostics Co., Ltd., and General Manager at Roche Diagnostics Shanghai Limited. His tenure with Roche spanned over two decades, where he held pivotal roles across Asia Pacific, Malaysia, and Shanghai, driving growth and innovation in the diagnostics sector. Starting his career as a Medical Technologist at The American Hospital of Singapore, Mr. Wong's dedication to advancing diagnostic solutions has made a lasting impact across the region.

Mr. Wong has received numerous accolades in recognition of his contributions, including the prestigious Chinese Government Friendship Award in 2016, the Shanghai Honorary Citizen title, and multiple Shanghai Magnolia Awards. His Outstanding Entrepreneur Award from the Shanghai Waigaoqiao Free Trade Zone further highlights his exceptional leadership. Through his strategic vision and commitment to medical innovation, Mr. Wong continues to influence and inspire the healthcare diagnostics industry.

Professor Christopher Laing



Since January 2020, Christopher Laing has served as Associate Professor (Practice Track) and Vice Dean of the Office of Innovation and Entrepreneurship at Duke-NUS, overseeing technology commercialization, industry collaborations, and innovation education. He also holds roles as Co-Chair of the SingHealth Duke-NUS Academic Medicine Innovation Institute and the Joint Centre for Technology and Development. Beyond forging strategic innovation and entrepreneurship partnerships for the School, he supports researchers/clinical innovators in project development and commercialization, and teaches early-career professionals on these topics.

In 2022, Chris took a one-year leave from Duke-NUS to act as the inaugural Chief Executive of ClavystBio, which builds Singapore's life sciences ecosystem via startup investments, university engagement, and collaboration on the Science Park 1 life sciences innovation district.

Prior to relocating to Singapore (2017–2019), he was the inaugural Executive Director of Capital City Innovation, coordinating stakeholders for Austin's health-focused innovation district—anchored by the University of Texas at Austin's Dell Medical School and partners, and recognized as an emerging hub by the National League of Cities and Association of University Research Parks.

Earlier, Chris was part of the senior management team at Philadelphia's University City Science Center (the U.S.'s oldest/largest urban innovation hub), managing ties with over 30 academic institutions and overseeing commercialization programs, startup investments, and incubation/acceleration, engaging 300+ innovators and projects.

A 2015 Eisenhower Fellow (engaging with China's urban innovation leaders), Chris is a member of the Philadelphia College of Physicians and Royal College of Veterinary Surgeons. His prior experience includes work at life sciences startups, leading a University of Pennsylvania research program, and practicing companion animal veterinary medicine in the UK.

He earned his veterinary training and PhD in endocrinology from the University of Sydney and completed post-doctoral training in molecular biology at the University of Pennsylvania's School of Medicine.

Agenda

Dress Code: Business Casual

<u>Sept. 26th, 2025, Friday</u>		
Venue: Conference Center, Duke Kunshan University, Kunshan, China		
Time	Topic	Speaker/ Organization
03:00 pm – 06:00 pm	Registration @ Duke Kunshan Conference Center (Close to university gate)	
05:00 pm -- 06:00 pm	(Optional) Campus Tour (Gather at DKU Conference Center lobby)	
06:00 pm – 08:00 pm	Welcome Dinner , Executive Dining, Academic Building, Duke Kunshan University	
<u>Sept. 27th, 2025, Saturday</u>		
Venue: Visitor Center, Duke Kunshan University, Kunshan, China		
08:30 am	Registration – Welcome Photo and “Ask Cards”	
09:00 am	Program Opening	Mr. Liang YU Associate Director Executive Education and Lifelong Learning Duke Kunshan University
09:05 am	Welcome Speech	Prof. Fujie XU Co-Director Global Health Research Center Duke Kunshan University Prof. John CW LIM Duke-NUS Center of Regulatory Excellence (CoRE) Founding Executive Director of the CoRE Dr. Wenfeng GONG Deputy Director Health Innovation and Partnership China Country Office Gates Foundation

09:20 am	Speed Icebreaking with “Ask Cards”	Mr. Liang YU Associate Director Executive Education and Lifelong Learning Duke Kunshan University
09:30 am	<u>Plenary Session</u> To be determined	Mr. Ming CHEN (TBD) Director, Pharmaceutical Development Division Department of Consumer Goods Industry Ministry of Industry and Information Technology
09:50 am	<u>Plenary Session</u> Leading IVD Business Going Global	Dr. L. Rizka ANDALUCIA Director General Pharmaceutical and Medical Devices Ministry of Health, Indonesia
10:10 am	<u>Plenary Session</u> The Key Imperatives We Hope to Address Through the EDP	Mr. Fatt-Heng WONG Program Co-orchestrator Founder, Shanghai IVD Consulting Company CREATInG Initiative Advisory Board Member Prof. Christopher LAING Program Co-orchestrator Vice Dean Office for Innovation & Entrepreneurship Duke-NUS Medical School
10:30 am	Refreshment Break/Group Photo	
Strategic Decision for Market Expansion		
11:00 am	<u>Plenary Session</u> Purpose and Ambition of Your Market Expansion	Mr. Zhou SONGYANG Founder and Chairman Pluslife
11:15 am	<u>Plenary Session</u> The Inner Power of a Leader: Vision, Mission, Values and the Leadership Practice	Prof. Christopher LAING Program Co-orchestrator Vice Dean Office for Innovation & Entrepreneurship Duke-NUS Medical School
11:30 am	<u>Panel Discussion</u> Purpose and Mission of Your Global Venture	Moderator Prof. Christopher LAING Program Co-orchestrator Vice Dean Office for Innovation & Entrepreneurship Duke-NUS Medical School Panelists Dr. Hani KIM Executive Director Right Foundation

		<p>Dr. Sidney YEE (Virtual) Founding CEO Diagnostics Development (DxD) Hub Adjunct Associate Professor CoRE, Duke-NUS Medical School</p> <p>Ms. Sabrina LI CEO & Founder Coyote Bio</p> <p>Ms. Fiona YU Partner Northern Light Venture Capital</p>
12:15 pm	Lunch	
12:30 pm	<p><u>Lunch and Learn (optional) – Administration Building 1212</u> How to Do Secondary Market Research to Understand Burden of Disease, Demand and Gap for IVD Products in Specific Country Market?</p>	<p>Mr. Lei GUO Research Fellow Health Policy and Systems Global Health Research Center Duke Kunshan University</p>
01:15 pm	<p><u>Panel Discussion</u> Co-creating an Ecosystem for IVD Access in Global Markets – Government and Hospital Perspectives</p>	<p>Moderator Prof. John CW LIM Duke-NUS Center of Regulatory Excellence (CoRE) Founding Executive Director of the CoRE</p> <p>Dr. L. Rizka ANDALUCIA Director General Pharmaceutical and Medical Devices Ministry of Health, Indonesia</p> <p>Mr. Jizong LI (Virtual) Deputy Director National Innovation Center for Excellence Director Shanghai Global Health Innovation Institute</p> <p>Prof. Jinghua CAO Director for International Collaboration Chinese Society of Biotechnology, Former Director, Bureau of International Cooperation, Chinese Academy of Sciences</p> <p>Mr. Yong XU Party Secretary, Shenzhen 3rd hospital, Director, Shenzhen IVD Concept Validation Center</p>
02:00 pm	<p><u>Group Work</u> Develop Key Criteria for Market Selection</p>	<p>Moderator Mr. Liang YU</p>

		Associate Director Executive Education and Lifelong Learning Duke Kunshan University
02:30 pm	<u>Panel Discussion</u> Making Market Entry Decisions	<p>Moderator Prof. Christopher LAING Program Co-orchestrator Vice Dean Office for Innovation & Entrepreneurship Duke-NUS Medical School</p> <p>Panelists Ms. Sabrina LI CEO & Founder Coyote Bio</p> <p>Ms. Di RONG Director Department of Medical Devices China Chamber of Commerce for Import and Export of Medicines and Health Products</p> <p>Mr. Han ZHAO Founder, Beijing Fangtang Hanhe Biotechnology Co., Ltd.</p>
03:15 pm	<u>Capturing the Insights for Your Company</u> Strategic Decision for Market Expansion	Mr. Fatt-Heng WONG Program Co-orchestrator Founder, Shanghai IVD Consulting Company CREATInG Initiative Advisory Board Member
03:30 pm	<u>Refreshment Break</u>	
Managing Risks for Global Ventures and Establishing the Right Governance Structure		
04:00 pm	<u>Plenary Session</u> Managing Legal Risks for Global Ventures	Mr. Weidong WANG Counsel Zhonglun Law Firm
05:00 pm	Group Q&A for Day 1	Mr. Liang YU Associate Director Executive Education and Lifelong Learning, Duke Kunshan University
05:15 pm	Conclusion for Day 1	Ms Xiaofan ZENG Senior Program Officer China Country Office Gates Foundation
05:30 pm	Day 1 Program Ends	
06:00 pm	Networking Dinner @ Kunchef in Dayu Bay (10-minute walking distance)	All

	7:30 pm music fountain performance@Dayu Bay	
08: 00 pm	End	
<p><u>Sept. 28th, 2025, Sunday</u></p> <p>Venue: Visitor Center, Duke Kunshan University, Kunshan, China</p>		
Time	Topic	Speaker/ Organization
08:30am	Registration	
09:00am	Icebreaking and Reflection	<p>Mr. Liang YU Associate Director Executive Education and Lifelong Learning Duke Kunshan University</p>
09:20am	<u>Capturing the Insights for Your Company</u> Day 1 Content Review	<p>Mr. Fatt-Heng WONG Program Co-orchestrator Founder, Shanghai IVD Consulting Company CREATInG Initiative Advisory Board Member</p>
Market Access		
09:45am	<p><u>Panel Discussion:</u> Product Pricing, Reimbursement and Procurement</p>	<p>Moderator Prof. Shenglan TANG Co-Director Global Health Research Center Duke Kunshan University</p> <p>Panelists Di DONG Senior Health Economist World Bank Group</p> <p>Mr. Derek LEE Chief Strategy Officer iGENETECH</p> <p>Mr. Trevor PETER (Virtual) Senior Director Global Diagnostics Team Clinton Health Access Initiative</p>
10:30am	<u>Refreshment Break</u>	
11:00 am	<p><u>Plenary Session</u> Paradigm shift in facilitating access - Regulatory Agility and Convergence in Product and Health Service Regulation</p>	<p>Prof. John CW LIM Duke-NUS Center of Regulatory Excellence (CoRE) Founding Executive Director of the CoRE</p>
Go-to-Market and Market Adoption		

11:30 am	<u>Panel Discussion</u> Go-to-market and market adoption in LMIC	Moderator Prof. Christopher LAING Program Co-orchestrator Vice Dean Office for Innovation & Entrepreneurship Duke-NUS Medical School Panelists Mr. Jeremy KOU Chairman Assistant, Coyote BioTech Mr. Arielle ZHANG Area Manager, International Business Center, Wantai Biopharm Mr. Pinxiong WANG Head of Overseas Sales, Aucheer Biotechnology
12:15pm	Lunch	
01:15 pm	<u>Panel Discussion</u> Overcome Operations and Finance Challenges Going to New Markets	Prof. Fujie XU Co-Director Global Health Research Center Duke Kunshan University Panelists Prof. Shenglan TANG Co-Director, Global Health Research Center, Duke Kunshan University Mr. Derek LEE Chief Strategy Officer iGENETECH Mr. Noah CHEN CEO, Pluslife
02:00 pm	<u>Capturing the Insights for Your Company</u> Go to Market and Market Adoption	Mr. Fatt-Heng WONG Program Co-orchestrator Shanghai IVD Consulting Company CREATInG Initiative Advisory Board Member
Managing Teams, Monitoring Performance and Dealing with Cultural Differences		
02:15 pm	Managing Global Teams and Dealing with Cultural Difference	Prof. Danielle CHANG Professor Language and Culture Center Duke Kunshan University
02:45 pm	Refreshment break	
03:15 pm	<u>Panel Discussion</u> Managing Teams, Monitoring Performance and Dealing with Cultural Difference	Moderator Elaine LIN Leadership Development Coach Former Vice President Asia-Pacific Human Resource



		<p>Baxter Healthcare Panelists Syed S AHMED (virtual) Director and CEO Techinvention Lifecare Limited</p> <p>Mr. Han XIA Founder and CEO, Hugo BioTech</p> <p>Prof. Danielle CHANG Professor, Language and Culture Center, Duke Kunshan University</p>
04:00 pm	<u>Capturing the Insights for Your Company</u> Managing Teams, Monitoring Performance and Dealing with Cultural Difference	<p>Mr. Fatt-Heng WONG Program Co-orchestrator Shanghai IVD Consulting Company CREATInG Initiative Advisory Board Member</p>
04:15 pm	Group Q&A for Day 2	<p>Mr. Liang YU Associate Director Executive Education and Lifelong Learning, Duke Kunshan University</p>
04:30 pm	Introducing Functional Training and Follow Up Activities of the CREATInG Initiative	<p>Prof. James LEONG Head Health Products & Regulatory Science CoRE, Duke-NUS</p>
04:45 pm	Conclusion and Call for Actions	<p>Prof. Wei Chuen TAN-KOI Lead Regulatory Systems Strengthening CoRE, Duke-NUS Medical School</p> <p>Ms. Xiaofan ZENG Lead, Senior Program Officer China Country Office Gates Foundation</p> <p>Mr. Liang YU Associate Director Executive Education and Lifelong Learning, Duke Kunshan University</p>
05:00 pm	Evaluation and Reflection	<p>Mr. Liang YU Associate Director Executive Education and Lifelong Learning Duke Kunshan University</p>
05:00 pm	End	
06:00 pm	Networking Dinner (Duke Kunshan Executive Dining, Academic Building)	



Sept. 29^h, 2025, Monday

Venue: Shanghai, Zhangjiang High

07:15 am	Shuttle bust Enroute to Shanghai	
10:00 am	<p>Immersion in Shanghai: Pfizer (China) Research & Development Co., Ltd., Address: Building 3, Ascendas Lotus Business Park, Lane 60, Naxian Road, Pudong ZhangJiang Hi-tech. Park, Shanghai, 201203, China.</p>	Pfizer China Open Innovation Center
11:30 am	Singapore as a Global Soft-Landing Site	<p>Prof. Christopher LAING Program Co-orchestrator Vice Dean Office for Innovation & Entrepreneurship Duke-NUS Medical School</p>
11:45 am	Program Conclusion	<p>Prof. Shenglan TANG Co-Director Global Health Research Center Duke Kunshan University</p> <p>Prof. John CW LIM Duke-NUS Center of Regulatory Excellence (CoRE) Founding Executive Director of the CoRE</p>
12:00 pm	End	

Speakers

Name	Designation & Biography
<p>Ms. Arielle ZHANG</p> <p>Area Manager, International Business Center, Wantai Biopharm</p> 	<p>Wenxuan Zhang holds a master's degree from University College London and has been working at Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. since 2016. He has extensive experience in overseas registration and certification, having participated in ISO 13485, CE, IVDD/IVDR, EU IVD clinical trials, and WHO PQ certifications. He is well-versed in quality management systems for IVD manufacturers and external audits, and has led his team to complete more than ten new product overseas registrations. In addition, he is familiar with the international medical device market environment, possesses a distribution network for medical devices in Europe, and manages Wantai's distribution and OEM business in Europe. His responsibilities include market access strategy, relationship network development, after-sales support, and team leadership. He has also been involved in international bidding projects with the Global Fund, the Gates Foundation, and the World Bank.</p>
<p>Prof. Danielle CHANG</p> <p>Language and Culture Center, Duke Kunshan University</p> 	<p>Chang's research interests focus on the area of pragmatic and effective communication in academic and commercial environments, particularly in a cross-cultural setting.</p> <p>Chang taught English enhancement and cross-culture communication classes at Shanghai Jiao Tong University for the last couple years. Before that she worked as a risk management consultant and risk communication trainer for companies in Europe, Israel and China.</p> <p>Chang has a B.A. in communication studies from University of California, Los Angeles and an M.A. in the same discipline from Stanford University.</p>

<p>Mr Derek LEE</p> <p>Chief Strategic Officer, iGENETECH</p> 	<p>Mr Lee is a seasoned leader in the in vitro diagnostics (IVD) industry with expertise spanning immunoassay, molecular diagnostics, and next-generation sequencing (NGS). He currently serves as the Chief Strategic Officer at iGENETECH, a precision diagnostics company based in South Korea, where he leads global strategy, partnerships, and innovation initiatives.</p> <p>He began his academic journey with a Bachelor of Medical Science from the Australian National University, followed by an MBA from Sungkyunkwan University (SKKU) in Korea, equipping him with a strong foundation in both biomedical science and business strategy.</p> <p>His professional career includes pivotal roles in leading Korean biotech companies. At MacroGen, a global genomics service provider, he led the Strategic Planning Team, overseeing business development and cross-border collaborations. He then joined SD Biosensor, a major player in diagnostics, as Director of Global Health Affairs Department, where he worked closely with global health organizations and stakeholders on infectious disease diagnostics and access initiatives.</p> <p>With a deep understanding of both the science and business of diagnostics, Mr Lee brings a global perspective and mission-driven approach to healthcare innovation, especially in the areas of emerging infectious diseases and public health.</p>
<p>Dr. Di DONG</p> <p>Senior Health Economist, World Bank Group</p> 	<p>Di Dong is a senior Health Economist in the Health, Nutrition, and Population Global Practice of the World Bank. She works on health financing, health service delivery, and hospital management in the Middle-east, Africa, and Asia, covering high-income countries, low-income countries, and fragile states. Di received her Ph.D. in Health Economics and Bachelor in Biomedical Sciences from the National University of Singapore.</p>

Ms. Di RONG

Director, Department of Medical Devices, China Chamber of Commerce for Import and Export of Medicines and Health Products



Ms. Rong Di, who holds a Master's degree in Pharmaceutical Chemistry from Shenyang Pharmaceutical University, currently serves as Director of the Medical Devices Department at the China Chamber of Commerce for Import and Export of Medicines & Health Products (CCCMHPIE).

She has long been engaged in coordinating and promoting foreign trade in the medical and health industry. Her main responsibilities include providing coordination, guidance, consultation, and services for the medical devices import and export sector, as well as conducting monitoring of key commodities and research and analysis on market operation. She has written a large number of research reports for government departments to reference in decision-making, participated in relevant research projects, and published dozens of industry analysis articles in professional newspapers and periodicals within the industry.

Meanwhile, she promotes the international development of the industry, conducts international exchanges and cooperation in the sector, and organizes and plans activities such as industry conferences and forums.

Ms. Elaine Lin

Leadership Development Coach, Former Vice President, Asia-Pacific Human Resource, Baxter Healthcare



Elaine Lin is a seasoned human resources executive turned independent leadership coach and consultant. With over 30 years of experience across China and Asia Pacific, she has held senior HR leadership roles, including Vice President of HR for Asia Pacific at Vantive and Baxter, where she led HR strategy across 14 markets.

Elaine is recognized for her expertise in talent management, organizational development, and change management. She has a strong track record of partnering with senior leaders to build leadership capabilities, strengthen employee engagement, and drive business performance.

Earlier in her career, she held senior HR positions at Accenture and Schering-Plough. Today, she brings her experience and passion for developing people into her coaching and advisory work, helping leaders and organizations navigate change and achieve sustainable growth.

Elaine holds an Executive MBA from Strathclyde University and a bachelor's degree from Beijing Technology and Business University.

Ms. Fiona YU

Partner, Northern Light Venture Capital



Fiona joined NLVC in 2014, bringing to the firm more than 10 years of experience in the healthcare industry and her strong strategic consulting skillset. Since joining NLVC, Fiona has helped grow the company's portfolio of healthcare investments to more than 60 companies spanning the biotechnology, diagnostics, digital health, and medical technology spaces. To date, she has been the lead investor on 15 of those investments, and she sits on the boards of five of those organizations. Currently, she works closely with a number of companies, including Cytek Biosciences, Taimei, and Immune-Onc.

Prior to NLVC, Fiona worked at Johnson & Johnson for more than seven years, and she also worked in Monitor Deloitte, serving local and multi-national healthcare companies through strategic consulting services.

Fiona holds a BS degree from the Beijing University of Aeronautics and Astronautics and an MBA from Duke University.

Mr. Han XIA

CEO & Founder, Hugobiotech



Bachelor's degree in Life Science from Fudan University and a Master's degree in Molecular Biology and Bioinformatics from Uppsala University, and is currently pursuing a Ph.D. in Control Science and Engineering at Xi'an Jiaotong University

Over ten years of experience at Novo Nordisk, where he served in roles including Executive Assistant to the European President and Head of the Northern China region, participating in the prelaunch and launch projects for Liraglutide.

76 articles(H-index of 17), Committee Member of the Standardization of Medical High-throughput Sequencing Technology and a Standing Committee Member of the third session of the China Medicinal Biotech Association (CMBA) for Biodiagnostic Technology.

Mr. Han ZHAO

Founder, Beijing Fangtang Hanhe Biotechnology Co., Ltd.



Founder of Beijing Fangtang Hanhe Biotechnology Co., Ltd. Former International RA Director at Sansure Biotech Inc. With over 12 years of experience in international project management and international collaboration, he has successfully led 4 WHO prequalification projects for domestic IVD products, as well as projects against other major regulatory authorities such as EU IVDD/IVDR, ANVISA, and FDA 510(K). Currently provides global market access and project management consulting services for domestic IVD enterprises.

Dr. Hani KIM

Executive Director, Right Foundation



Hani Kim is the Executive Director of the RIGHT foundation based in Seoul, Korea, with 19 years of experience in biomedical research in academia and global health R&D funding organizations.

She completed her PhD in Lab Medicine and Pathobiology at the University of Toronto, Canada and post-doctoral training in molecular immunology at the Max-Planck Institute of Immunology, Germany, and an MPH at the Johns Hopkins School of Public Health, where she later served as a Research Associate and trained research officers at the icddr,b in Bangladesh and the Kenyan Medical Research Institute.

Prior to joining the RIGHT foundation in 2021, she developed and managed portfolios of vaccine discovery grants and molecular surveillance grants at the Gates Foundation in Seattle for 6.5 years. Hani has strong interests in the political origins of health inequity. Her recent articles include 'We need people's WHO to solve vaccine inequity, and we need it now', 'The implicit ideological function of the global health field and its role in maintaining relations of power', 'The sociopolitical context of the COVID-19 response in South Korea', and 'A critical assessment of the ideological underpinnings of current practice in global health and their historical origins'.

Mr. Jeremy KOU

Chairman Assistant, Coyote Bioscience



Master in English Literature and Linguistics from China Foreign Affairs University and MBA from University College London in United Kingdom. He has been committed himself to international business and trading for over 15 years.

Since April 2020, he joined in Coyote Bioscience and expanded the international business development with his experience in sales and distribution channels and market penetration. He helped the company products access to more than 65 countries in Europe, Middle East, Southeast Asia and Latin America with CE-IVDD/IVDR. In coming years, we will have more NMPA, CE-IVDR, FDA and WHO PQ tests approved in infectious diseases and companion diagnostics, and more active installations in hospitals, clinics and even drug stores worldwide. Making quality product and satisfying our customers will make Coyote the leader of Molecular Diagnostics POCT in China and worldwide.

Prof. Jinghua CAO

**Director for International Collaboration,
 Chinese Society of Biotechnology
 Former Director, Breau of International
 Cooperation, Chinese Academy of
 Sciences**



Prof. CAO Jinghua, Director, Committee for International Cooperation and Overseas Affairs of the Chinese Society of Biotechnology. Prior to this position, he served as Executive Director of the Secretariat of the Alliance of International Science Organizations (ANSO). As an international cooperation specialist, he worked in different posts in international affairs at the Chinese Academy of Sciences (CAS) such as Deputy Director of the Office of External Financing, CAS, Deputy Director and Director of the Office of American and Oceanian Affairs of the Bureau of International Cooperation (BIC), CAS, Assistant Director, Deputy Director General and Director General of BIC. He also worked as Second and First Secretary in the S&T Section of the Chinese Embassy in Washington D.C. from 1995 to 1997. His research interests are science policy and international cooperation in science and engineering. His publication includes a few articles in international SCI journals.

Mr. Jizong LI

Deputy Director, National Innovation Center for Excellence



Jizong Li is the Deputy Director of the Yangtze River Delta National Technology Innovation Center and the Deputy Director of the Shanghai Institute of Biopharmaceutical Technology. He has long been engaged in the management of biopharmaceutical research projects, technical services, achievement transformation, and policy research.

Dr L. Rizka ANDALUCIA

Director General for Pharmaceutical and Medical Devices, Ministry of Health, Indonesia



Dr L. Rizka Andalucia, M.Pharm is a distinguished health professional with deep expertise in global health governance and a proven track record of driving strategic decision-making. She currently serves as the Director General of Pharmaceuticals and Medical Devices at the Ministry of Health of Indonesia, where she plays a critical role in shaping policies that advance equitable access to essential medicines, vaccines, and medical technologies particularly in Low-and-Middle Income Countries (LMICs).

Dr Rizka's leadership is built on a solid foundation. Beginning her professional journey as a pharmacist, her academic path continued with advanced studies, culminating in a Doctorate in Biomedical and Medical Sciences. With a public service career spanning more than three decades since 1994, she has consistently brought together science and policy to lead in critical areas such as pharmaceutical development, regulatory governance, and resource mobilization, all aligned with the broader goals of global health equity.

Driven by a strong vision to strengthen local production as a cornerstone of national health resilience, Dr Rizka leverages her influential international roles to advance this mission. Her expertise is sought globally, serving as a Board Member for the Coalition for Epidemic Preparedness Innovations (CEPI), a member of the M72 Advisory Board, the Focal Point for the Regional Vaccine Manufacturing Collaborative (RVMC), and an advisory board member for The Indonesian Association for the Study of Medicinals (IASMED). This global presence, including in forums like the G20, allows her to bridge international priorities with local realities, fostering a robust R&D ecosystem that supports long-term healthcare sustainability.

Mr. Lei GUO

Research Fellow in Health Policy and Systems, Senior Research Fellow, Innovation Lab for Vaccine Delivery Research



Lei Guo is currently a Research Fellow in Health Policy and Systems at the Global Health Research Center, Duke Kunshan University, and a Senior Research Fellow at the Innovation Lab for Vaccine Delivery Research. His research focuses on vaccination service research, evaluation of public health interventions, and performance improvement in health systems. He leads a study on the cost and optimization of vaccination service delivery in Kunshan, contributes to evaluations of newborn screening programs for congenital heart disease and hearing impairment, and provides technical and managerial support to the Innovation Lab for Vaccine Delivery. He also participates in research projects on non-NIP (non-National Immunization Program) vaccines in China and supports work related to China's achievement of health-related Sustainable Development Goals.

Previously, Lei worked with the World Bank, the Bill & Melinda Gates Foundation, and the Duke Global Health Institute in various research and consultancy roles. He contributed to studies on tuberculosis control, COVID-19 response, and health financing systems, and provided technical support on data analysis for pandemic response evaluations in the Gulf Cooperation Council countries. He has coordinated and supported collaborative projects with institutions such as the China National Health Development Research Center and Fudan University, and has supervised undergraduate students, graduate students, and interns in research.

Lei holds a Master of Science in Global Health from Duke University and a Bachelor of Science in Biomedical English from Peking University. His research has been published in international journals including PLOS Medicine, The Lancet Public Health, and BMJ Global Health. He has also contributed to multiple health policy reports, book chapters, and policy briefs. His research interests include immunization service delivery systems, health resource allocation, public health strategy analysis, and data-driven policy development.

Asst Prof LEONG James

Head; Health Products & Regulatory Science, CoRE, Duke-NUS Medical School



As the Head of Health Products & Regulatory Science at the Centre of Regulatory Excellence, Asst Prof James Leong is in charge of identifying the educational needs for the various stakeholders involved in regulatory affairs in the Asia Pacific region, and establishing education roadmaps, priorities and deliverables.

In this role, he actively conducts roundtable discussions on policy with regulatory affairs professionals across Asia Pacific, as well as research on advancing regulatory sciences. He draws his regulatory experience from his years as a senior regulatory specialist with the Health Sciences Authority of Singapore, where he is a clinical reviewer in addition to managing the post-market benefit-risk assessments and regulatory actions, as well as oversees the training of clinical assessors. In addition to his Masters in clinical pharmacy, he is also Board-certified in pharmacotherapy. His previous clinical experiences include leading the hospital drug information services and heart failure clinic.

He obtained his PhD from Cardiff University, focusing on benefit-risk assessment frameworks, communication of regulatory decisions and innovation of regulatory approaches.

Mr. Liang YU



Associate Director of Executive Education and Lifelong Learning, Duke Kunshan University





Mr Liang Yu is passionate about business education, leadership development and entrepreneurship. He has over 20 years of experience in the corporate education sector, and his responsibilities include strategic planning and execution, educational startup, product development, program design, marketing & complex sales and operational excellence. Mr Yu currently works in Duke Kunshan University overseeing its executive education business. He partners with leading companies to grow their leadership and organizational capability and enjoys the process of designing transformational learning journey for leaders around the world.

Prior to Duke Kunshan, Mr Yu has worked for Deloitte Consulting in organizational change practice and Duke Corporate Education in Senior Executive Development. Mr Yu is passionate about developing future leaders in the digital age in a responsible and sustainable manner.

His current research focuses on developing purposeful and collaborative global leaders in the digital age, and his research paper is included in edited volumes with Routledge and Palgrave Macmillan. The case Mr Yu authored Finding Balance Between Flexibility and Stability has won Harvard Business Review's (Chinese Edition) Ram Charan Management Practice Award in 2024. He translated Giving Voice to Values—a masterpiece for value-driven leadership written by Prof Mary Gentile—into Chinese.

	<p>Mr Yu loves reading about philosophy, ethics, politics, entrepreneurship, higher education, cross culture leadership and linguistics. He holds an MBA degree from Fuqua School of Business at Duke University where he served as a COLE Leadership Fellow during 2012-2013. He lives in Kunshan China with his family.</p>
<p>Mr. Pinxiong WANG</p> <p>Head of Overseas Sales, Aucheer, Biotechnology</p> 	<p>Mr. Pingxiong WANG has a 6-year working experience at the Center for Disease Control and Prevention (CDC), where he specialized in the prevention and control of HIV and other Sexually Transmitted Diseases (STDs), and possesses a solid public health background. Additionally, he has 6 years of experience in the medical device/In Vitro Diagnostic (IVD) industry. His professional footprint has covered nearly 20 countries across 5 continents worldwide. He played a crucial role in achieving the critical "from 0 to 1" breakthrough in overseas sales business for two companies (KFBIO and Aucheer) and established an extensive network of distributors.</p>
<p>Asst Prof TAN-KOI Wei Chuen</p> <p>Lead, Regulatory Systems, Strengthening, CoRE, Duke-NUS Medical School</p> 	<p>Asst. Prof Tan-Koi Wei Chuen is Lead of Regulatory Systems Strengthening at CoRE. Her work focuses on health policy research and capacity building in biomedical innovation and regulatory science. Her portfolio includes international capacity building programmes, as well as regulatory systems strengthening projects funded by the Asian Development Bank and the Gates Foundation on vaccine and in-vitro diagnostic regulation.</p> <p>Prior to joining Duke-NUS Medical School, Asst. Prof Tan-Koi was Regulatory Consultant and Team Lead of the Regulatory Research and Risk Communication teams at Singapore's Health Sciences Authority.</p> <p>A pharmacist by training, Asst. Prof Tan-Koi was awarded the Singapore Health Manpower Development Plan Fellowship for the Graduate Research Programme in Public Health and received her doctoral degree from the NUS Saw Swee Hock School of Public Health.</p>

<p>Mr. Trevor PETER</p> <p>Senior Director, Global Diagnostics Team, Clinton Health Access Initiative</p> 	<p>Trevor Peter PhD MPH MBA is the head of Diagnostics at the Clinton Health Access Initiative where he oversees programs implementing novel diagnostics, especially in Africa and Asia. Dr. Peter is an epidemiologist a senior advisor on diagnostics technologies and testing services to governments, the WHO, Global Fund, US Centers for Disease Control and other organizations. He also conducts extensive research on health systems strengthening and on the health benefits of improved diagnostic technologies, especially in low-resource settings. Previously he managed the Botswana-Harvard HIV Reference Laboratory and conducted research in animal health.</p>
<p>Ms Sabrina LI</p> <p>Senior Engineer, Founder & CEO of Coyote Bioscience</p> 	<p>Bachelor in Physics from Peking University, Master in Physics from University of California at San Diego, Deputy Director of the healthcare expert committee at Beijing Overseas Talents Association, 2020 Fortune China's "40 under 40", Sabrina Li founded Coyote Bioscience in 2009, with a belief that everyone can be benefited from molecular diagnostics. Over the past decade, she and her team have been committed in the molecular diagnostics space with a focus on point-of-care rapid nucleic acid detection technology for pathogenic microorganism. The technology has empowered community level health facilities to conduct effective health screening projects, significantly improving people's access to infectious disease prevention, cancer screening, precision medicine, with her achievement in advancing medical technology.</p> <p>Based on the interdisciplinary "BT+IT" innovation of synthetic biology, lab-on-chip, and robotic technology, in 2024, Coyote Bio launched the world's fastest molecular diagnostic AI robot with All-in-One integrated Bio-Chip (8 mins' SARS-CoV-2 test with NMPA and CEIVDR). The platform won National Award of Scientific and Technological Progress in 2024.</p>
<p>Dr Sidney YEE</p> <p>Adjunct Associate Professor, CoRE, Duke-NUS Medical School</p>	<p>Dr Sidney Yee is founding CEO of Diagnostics Development (DxD) Hub, a national platform hosted by Singapore's Agency for Science, Technology and Research (A*STAR). DxD Hub is a design, development and productization hub for diagnostics innovations, with expertise and capability to rapidly translate R&D output from public and private sectors into deployable products in the market.</p> <p>During the COVID-19 pandemic, the capabilities of DxD Hub helped to develop and deploy several COVID-19 diagnostics</p>




products within months. These products included conventional RT-PCR test Fortitude, serological test C-Pass, and direct PCR test RESOLUTE. Fortitude was the first diagnostic kit to be granted provisional authorisation by Singapore's Health Sciences Authority (HSA) and was deployed in more than 45 countries globally. C-Pass is the only COVID-19 neutralising antibody test approved by HSA, US-FDA and CE. For her contributions during the pandemic, Dr Yee was conferred the Public Administration Gold Medal by the Prime Minister's Office.

Dr Yee is founding co-chair of the ASEAN Diagnostics Development Initiative, which was endorsed by the ASEAN Committee of Science, Technology and Innovation in May 2018. Its mandate is to develop diagnostic products that address unmet clinical needs in ASEAN by ASEAN Member States. The objectives are diagnostics capacity building in ASEAN Member States, with a focus on bridging the translation gap to develop implementable diagnostics solutions and to improve human health and the healthcare industry in ASEAN.

She is Venture Partner with iGlobe Partners Ventures, Board member on several biotech companies such as INEX Innovate, Moleac, Mediven etc, as well as Governing Board member and strategic advisor on various Singapore national platforms such as NAMIC, NHIC, IDMXS etc.



Mr. Zhou SONGYANG
Founder and Chairman, Pluslife



Professor and Doctoral Supervisor at the School of Life Sciences, Sun Yat-sen University (SYSU); Director of the SYSU Anti-Aging Center; Director of the Guangzhou Key Laboratory of Anti-Aging; and Chief Scientist of National Major Scientific Research Programs and Key Special Projects.

He earned a PhD in Molecular and Cellular Physiology from Tufts University in Boston, USA, in 1995, and subsequently pursued postdoctoral research at Harvard Medical School and the Massachusetts Institute of Technology (MIT). Starting from 1998, he served successively as Assistant Professor, Associate Professor, and Full Professor in the Department of Biochemistry and Molecular Biology at Baylor College of Medicine (USA), and previously held positions as Director of Molecular Drug Discovery and Director of the RNAi Center. In 2009, he returned to China full-time and took office as Dean of the School of Life Sciences at SYSU (2009–2015). In 2011, he founded and has since served as Director of the SYSU Anti-Aging Center and the Guangzhou Key Laboratory of Anti-Aging.

Currently, he also serves as Vice Director of the Academic Committee of the National and Local Joint Engineering Laboratory for Vascular Disease Diagnosis and Treatment Technology (affiliated with The First Affiliated Hospital of SYSU). His research focuses on telomere regulation and aging mechanisms. He was the first to discover that six telomeric proteins (including TRF1) form the telosome/shelterin complex, proposed the concept of "Telomere Interactome," and developed technologies such as BiFC (Bimolecular Fluorescence Complementation), Protein-Fragment Complementation, and Oriented Peptide Library.

	<p>He has published papers in top journals including Nature, Cell, and Science, with a total of over 13,000 citations and an H-index of 75. Currently, he holds the position of Vice Leader of the Expert Group for the Major Research Plan on "Organ Aging" under the National Natural Science Foundation of China (NSFC), and serves as a Standing Director of the Chinese Society of Biochemistry and Molecular Biology. In 2025, he was elected Vice Chairman of the Professional Committee of Cardiovascular Basic Medicine under the China Medical Education Association.</p>
<p>Syed S AHMED</p> <p>Director and CEO, Techinvention Lifecare Limited</p> 	<p>Syed Saader Ahmed is the Founder & CEO of TechInvention Lifecare Pvt. Ltd. and Vice President of the Emerging Biopharmaceutical Manufacturers Network (EBPMN). He is a co-inventor on 15+ patents in vaccines, diagnostics, and biotherapeutics, and has published in leading journals. He has successfully led vaccine technology transfer and capacity-building projects across Latin America, Asia, and Africa, often supported by the World Bank and Asian Development Bank. A life member of major pharmaceutical and management associations, he holds a Bachelor of Pharmacy, an MBA, and is pursuing doctoral research on vaccine equity in LMICs. His mission is to advance global health equity through access to diagnostics, vaccines, and bio-therapeutics for all.</p>
<p>Mr. Weidong WANG</p> <p>Counsel, Zhonglun Law Firm</p> 	<p>Lawyer Weidong Wang has worked closely with entrepreneurs for many years, supporting the growth of start-up companies. He also represents venture capital and private equity funds in their investments in entrepreneurial enterprises. Mr. Wang has extensive experience in equity investment, mergers and acquisitions, capital markets, equity incentive plans, corporate governance and compliance, intellectual property, as well as litigation and arbitration. In the field of corporate acquisitions, he has represented numerous Fortune 500 companies in acquisition transactions and has participated in multiple domestic and overseas IPO projects. His practice focuses on sectors including life sciences and healthcare, carbon neutrality, telecommunications, media and technology, materials, semiconductors, and artificial intelligence.</p>

Dr Wenfeng GONG

Deputy Director, Health Innovation & Partnerships, China Country Office, Gates Foundation



Dr Wenfeng Gong leads a portfolio of health product development collaborations in China and other geographies, working to accelerate the translation, development, and commercialization of medical products—including drugs, vaccines, monoclonal antibodies, diagnostics, medical devices, and vector control technologies—to improve health outcomes in LMICs. His team plays a critical role in advancing the foundation’s global strategies for the prevention, control, and elimination of priority infectious diseases, including vaccine-preventable diseases, malaria, tuberculosis, HIV, polio, and pneumonia. His work also supports maternal, neonatal, and child nutrition and health innovations, ensuring that life-saving interventions reach those in need.

With over 15 years of experience in global health innovation and access, Wenfeng has led a wide range of high-impact projects. In previous roles, he led a portfolio of projects to monitor global vaccine demand and understand vaccination drivers using a combination of social science methods, epidemiology, and advanced analytics. He co-designed a strategy to accelerate new vaccine introductions in China through financial innovation, advocacy, and implementation science. He conducted consulting projects for Gavi and WHO, advising on investment strategies, program monitoring, technology transfer mechanisms, and vaccine cost-effectiveness assessments. He led a two-year research project in Pakistan, pioneering statistical and implementation innovations to enhance the efficiency and effectiveness of immunization program monitoring.

In addition to his role at the foundation, Dr Gong is an Adjunct Associate Professor at the Duke Global Health Institute, where he also serves on the Board of Advisors. He is a standing member of the Council for the Promotion of International Vaccine Cooperation under the China Association for Vaccines and previously served as a member of the WHO Expert Working Group on Behavior and Social Drivers of Vaccination. He also proudly volunteers as the co-president of the Parent Support Organization at the Concordia International School of Shanghai.

Ms Xiaofan ZENG

Senior Program Officer, China Country Office, Gates Foundation



Xiaofan Zeng is a Senior Program Office at the China Country Office, Gates foundation, responsible for global health innovation partnership in China and market access of key diagnostics products in LMICs. Xiaofan has over decade experience of diagnostics industry, especially in sequencing. Prior to Gates foundation, she worked as a Vice President at Qiming Venture Partners, where she led and participated in more than 20 deals, mainly focusing on diagnostics and life science tools. Before joining Qiming, she was a Director of the Science and Technology Management Office at BGI-Research. From 2015 to 2016, she studied bioethics and healthcare policy at King's College London as a Visiting Research Fellow. She received a BSc degree in Biotechnology from Sun Yat-sen University and a MSc degree in Biotechnology from Lund University, Sweden.

Mr. Yong XU

Party Secretary, Shenzhen 3rd hospital, Director, Shenzhen IVD Concept Validation Center



Xu Yong, male, holds MD and MHA degrees. He is currently Secretary of the CPC Committee of Shenzhen Third People's Hospital and Chairman of the National Center for Infectious Disease Clinical Medicine Research, with the title of Chief Clinical Laboratory Technician (Senior Professional Title, Level 2). He also serves as a doctoral/postdoctoral supervisor, Director of Shenzhen Key Laboratory of Hepatobiliary Disease Research and Shenzhen IVD Proof-of-Concept Center. A former senior visiting scholar at Nuremberg Center Hospital (affiliated with Germany's University of Erlangen-Nuremberg), he is now a tenured professor and doctoral supervisor at the School of Medicine, Southern University of Science and Technology, as well as a doctoral supervisor in molecular biology at Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.

In academic associations, he is a member of the Expert Committee for Modern Hospital Lean Management Project (Hospital Management Research Institute, National Health Commission), Vice Chairman of the Hospital Management Committee of Guangdong Hospital Association, and Chairman of the Integrative Medicine Professional Committee of Shenzhen Medical Association.

For research achievements: As project leader, he undertook a National Key Science and Technology Project (2023ZD0502402, with Sub-project 2: "Identification of High-risk Factors for Severe Infections and Construction of Multimodal Prediction Models") and a National Key R&D Program project (2022YFC2302700, Sub-project: "Research on Port Source Monitoring System and Its Application"). He presided over 2 projects of Guangdong Provincial Natural Science Foundation, 1 key laboratory project of Shenzhen Science and Technology Commission, 2 of Shenzhen Health Bureau, and 6 of Shenzhen Science and Technology Bureau, and participated in 1 provincial and 1 municipal key research project. He has published over 80 SCI papers, co-authored 1 foreign-language book, and obtained 3 national invention patents.



Stay updated with the latest insights



Visit our webpage to
view upcoming events!



Follow CoRE on
LinkedIn!

